Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1128Carcinoma, Non-Small-Cell Lung 718Neoplasms 545Prostatic Neoplasms 502Colorectal Neoplasms 438Multiple Myeloma 336Lung Neoplasms 309Neoplasm Metastasis 288Leukemia, Myeloid, Acute 263Stomach Neoplasms 248Carcinoma, Hepatocellular 245Ovarian Neoplasms 225Rectal Neoplasms 211Colonic Neoplasms 204Lymphoma, Follicular 200Lymphoma 199Leukemia 190Uterine Cervical Neoplasms 181Head and Neck Neoplasms 174Pancreatic Neoplasms 171Lymphoma, Non-Hodgkin 167Leukemia, Lymphocytic, Chronic, B-Cell 166Lymphoma, Large B-Cell, Diffuse 163Recurrence 161Melanoma 158Precursor Cell Lymphoblastic Leukemia-Lymphoma 154Squamous Cell Carcinoma of Head and Neck 147Pain 141Urinary Bladder Neoplasms 139Brain Neoplasms 133

Interventions

anlotinib 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Advanced Renal Cancer × Clear all
NCT04523272 2024-10-15

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Active not recruiting
528 enrolled

Advanced Renal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡